Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer
Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer
复制标题
DOI：
10.4238/2015.december.22.25
复制
发表时间：
2015-01-01
影响因子：
0.4
通讯作者：
Ma, C. F.
中科院分区：
文献类型：
--
作者：
Liu, P.;Xin, F.;Ma, C. F.
先前的研究已经报道miR-196 a在宫颈癌组织和细胞系中上调。然而，血清miR-196 a是否在宫颈癌或宫颈上皮内瘤变（CIN）患者中升高，其潜在的临床价值仍然未知。总共招募了105名宫颈癌患者、86名CIN患者和50名健康志愿者。进行定量逆转录-聚合酶链反应以比较所有参与者的血清miR-196 a水平。还检查了血清miR-196 a与宫颈癌CIN分级/临床病理参数之间的关系。使用Kaplan-Meier方法进行生存分析。采用单因素和多因素分析探讨宫颈癌的独立危险因素。宫颈癌患者血清miR-196 a水平显著高于健康对照组（P < 0.01），CIN患者血清miR-196 a水平显著高于健康对照组（P < 0.05）。血清miR-196 a与CIN分级和各种宫颈癌参数相关，包括肿瘤大小（P = 0.031）、淋巴结转移（P = 0.018）、FIGO分期（P = 0.004）和分级（P = 0.011）。血清miR-196 a水平较高的宫颈癌患者的总生存率较差（P = 0.004）。多因素分析显示，血清miR-196 a水平升高是宫颈癌患者生存不良的独立预测因子（HR = 3.510，95%CI = 1.961-6.874，P = 0.025）。总之，我们的研究结果表明，血清miR-196 a过表达与CIN分级和宫颈癌进展相关。因此，血清miR-196 a可能是宫颈癌早期检测和预后判断的可靠生物标志物。
Previous studies have reported that miR-196a is upregulated in cervical cancer tissues and cell lines. However, whether serum miR-196a is increased in patients with cervical cancer or cervical intraepithelial neoplasia (CIN), and its potential clinical value remained unknown. In total, 105 cervical cancer patients, 86 CIN patients, and 50 healthy volunteers were recruited. Quantitative reverse transcription-polymerase chain reaction was performed to compare the serum levels miR-196a in all participants. The associations between serum miR-196a and CIN grade/clinicopathological parameters of cervical cancer were also examined. A survival analysis was performed using the Kaplan-Meier method. Univariate and multivariate analyses were conducted to explore the independent risk factors for cervical cancer. Our results revealed that serum miR-196a levels were higher in patients with cervical cancer (P < 0.01) and CIN (P < 0.05) compared to those in healthy controls. Serum miR-196a was associated with CIN grade and various cervical cancer parameters including tumor size (P = 0.031), lymph node metastasis (P = 0.018), FIGO stage (P = 0.004), and grade (P = 0.011). Cervical cancer patients with higher serum miR-196a levels had a poorer overall survival rate (P = 0.004). Multivariate analysis revealed that high serum miR-196a was an independent predictor for poor survival of cervical cancer (HR = 3.510; 95% CI = 1.961-6.874; P = 0.025). In conclusion, our findings suggest that serum miR-196a overexpression is associated with CIN grade and cervical cancer progression. Therefore, serum miR-196a may be a reliable biomarker for early detection and prognosis of cervical cancer.